

[Hjem](#) [Medlemmer](#) [Prosjekter](#) [Publikasjoner](#) [Om forskningsgruppa](#) [English](#)

## Metabolisme og nyremedisin

Forskningsgruppen fokuserer på sammenhengen mellom metabolske forstyrrelser og nyresykdom, og betydningen for utvikling av hjerte/karsykdom.

Antallet personer med både kronisk nyresykdom og pasienter i nyreerstattende behandling er raskt økende. Dette utgjør et problem av stor helseøkonomisk betydning. Vi har fokus på problemstillingen: Er det sammenhenger mellom forstyrrelser i urinsyrenivå, eller i glukose- og lipid metabolismen, når det gjelder økning i blodtrykk, fall i nyrefunksjon og senere utvikling av hjerte- karsykdom?

Vi benytter en epidemiologisk tilnærming, kliniske studier, og også dyre-eksperimentelle studier

# Orosomucoïd, markør for tap av nyrefunksjon?



Runa Marie Andreassen, MD, PhD student

[runa.marie.andreassen@helgelandssykehuset.no](mailto:runa.marie.andreassen@helgelandssykehuset.no)





# Hvordan måles nyrefunksjonen?



$$\text{Excretion} = \text{Filtration} - \text{Reabsorption} + \text{Secretion}$$


kreatinin er et nedbrytningsprodukt fra muskler



kreatinin skilles ut i blodet



i nyrene fjernes kreatinin fra blodet



kreatinin skilles ut med urinen

Lever, nyre og pancreas syntetiserer kreatin, og i muskler og hjerne brukes det som energikilde. Kreatinin er en ubrukkelig metabolitt som må utskilles fra kroppen.



Kvinner med s-kreatinin  $\leq 62 \mu\text{mol/L}$ :  $\text{GFR (i mL/min/1,73m}^2) = 144 \times ((\text{s-kreatinin}/88,4)/0,7)^{-0,329} \times (0,993)^{\text{alder}}$   
Kvinner med s-kreatinin  $> 62 \mu\text{mol/L}$ :  $\text{GFR (i mL/min/1,73m}^2) = 144 \times ((\text{s-kreatinin}/88,4)/0,7)^{-1,209} \times (0,993)^{\text{alder}}$   
Menn med s-kreatinin  $\leq 80 \mu\text{mol/L}$ :  $\text{GFR (i mL/min/1,73m}^2) = 141 \times ((\text{s-kreatinin}/88,4)/0,9)^{-0,411} \times (0,993)^{\text{alder}}$   
Menn med s-kreatinin  $> 80 \mu\text{mol/L}$ :  $\text{GFR (i mL/min/1,73m}^2) = 141 \times ((\text{s-kreatinin}/88,4)/0,9)^{-1,209} \times (0,993)^{\text{alder}}$

GFR estimert med CKD-EPI formelen gir et bedre mål på nyrefunksjonen enn bruk av s-kreatinin alene. Dette er i dag den basale undersøkelsen for å diagnostisere kronisk nyresykdom.



# Hvorfor forske på nyreskade?

- Angår mange
- Stille sykdom i tidlig stadium
- Store kostnader for samfunnet
- Store helsemessige konsekvenser for den enkelte pasient
- Økt risiko for hjerte-kar sykdom og død
- Fokus på identifisere i tidlig stadium for å forebygge videre progresjon

# Biomarkører i urin

**Figur 1. Ny nomenklatur for beskrivelse av albuminuria. Nasjonal faglig retningslinje for behandling av diabetes (Helsedirektoratet). u-AKR (urin albumin kreatininratio)**

| U-AKR          | ALBUMINUTSKILLELSE        |
|----------------|---------------------------|
| <3 mg/mmol     | normal albuminutskillelse |
| 3-29 mg/mmol   | moderat albuminuria*      |
| 30-299 mg/mmol | betydelig albuminuria*    |
| ≥300 mg/mmol   | nefrotisk proteinuri      |

\*3-29 mg/mmol er tidligere benevnt som mikroalbuminuri


\*\*30-299 mg/mmol er tidligere benevnt som makroalbuminuri



Orosomuroid i urin



# Urinary orosomucoid – a better predictor of cardiovascular and renal disease than albuminuria?





## Urinary orosomuroid is associated with diastolic dysfunction and carotid arteriopathy in the general population. Cross-sectional data from the Tromsø study

Runa M. Andreassen<sup>a,b</sup>, Jens B. Kronborg<sup>b,c</sup>, Henrik Schirmer<sup>d,e,f</sup>, Ellisiv B. Mathiesen<sup>g,h</sup>, Toralf Melsom<sup>b,i</sup>, Bjørn O. Eriksen<sup>b,i</sup>, Trond G. Jenssen<sup>b,j</sup> and Marit D. Solbu<sup>b,i</sup>

<sup>a</sup>Department of Internal Medicine, Helgeland Hospital Trust, Sandnessjøen, Norway; <sup>b</sup>Metabolic and Renal Research Group, UiT The Arctic University of Norway, Tromsø, Norway; <sup>c</sup>Department of Immunology and Transfusion Medicine, Innlandet Hospital Trust, Lillehammer, Norway; <sup>d</sup>Department of Cardiology, Akershus University Hospital, Nordbyhagen, Norway; <sup>e</sup>The Cardiovascular Research Group, UiT The Arctic University of Norway, Tromsø, Norway; <sup>f</sup>Institute of Clinical Medicine, University of Oslo, Oslo, Norway; <sup>g</sup>Department of Neurology, University Hospital of North Norway, Tromsø, Norway; <sup>h</sup>Brain and Circulation Research Group, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway; <sup>i</sup>Section of Nephrology, University Hospital of North Norway, Tromsø, Norway; <sup>j</sup>Department of Transplant Medicine, Oslo University Hospital and University of Oslo, Oslo, Norway

### ABSTRACT

**Objectives.** Urinary albumin excretion is a risk marker for cardiovascular disease (CVD). Studies suggest that urinary orosomuroid may be a more sensitive marker of general endothelial dysfunction than albuminuria. The aim of this population-based cross-sectional study was to examine the associations between urinary orosomuroid to creatinine ratio (UOCR), urinary albumin to creatinine ratio (UACR) and subclinical CVD. **Design.** From the Tromsø Study (2007/2008), we included all men and women who had measurements of urinary orosomuroid ( $n = 7181$ ). Among these, 6963 were examined with ultrasound of the right carotid artery and 2245 with echocardiography. We assessed the associations between urinary markers and subclinical CVD measured as intima media thickness of the carotid artery, presence and area of carotid plaque and diastolic dysfunction (DD). UOCR and UACR were dichotomized as upper quartile versus the three lowest. **Results.** High UOCR, adjusted for UACR, age, cardiovascular risk factors and kidney function, was associated with presence of DD in men (OR: 3.18, 95% CI [1.27, 7.95],  $p = .013$ ), and presence of plaque (OR: 1.20, 95% CI [1.01, 1.44],  $p = .038$ ) and intima media thickness in women (OR: 1.34, 95% CI [1.09, 1.65],  $p = .005$ ). Analyses showed no significant interaction between sex and UOCR for any endpoints. UACR was not significantly associated with DD, but the associations with intima media thickness and plaque were of magnitudes comparable to those observed for UOCR. **Conclusions.** UOCR was positively associated with subclinical CVD. We need prospective studies to confirm whether UOCR is a clinically useful biomarker and to study possible sex differences.


### ARTICLE HISTORY

Received 15 November 2021  
Revised 4 May 2022  
Accepted 13 May 2022

### KEYWORDS

Orosomuroid; albumin;  
arteriopathy; epidemiology;  
general population

# Cross sectional Association



In conclusion, we have shown an association between UOCR and well accepted subclinical markers of CVD.

Table 4. Odds ratio for having subclinical cardiovascular disease.

|                   |        | OR for diastolic dysfunction               | OR for the presence of plaque              | OR for IMT in upper quartile               |
|-------------------|--------|--|--|--|
| <b>Model (A).</b> |        |  |  |  |
| UOCR              | women: | 1.78, 95% CI [0.83, 3.84], <i>p</i> = .141 | 1.38, 95% CI [1.17, 1.63], <i>p</i> < .001 | 1.48, 95% CI [1.22, 1.80], <i>p</i> < .001 |
| ≥ upper quartile  | men:   | 3.78, 95% CI [1.64, 8.69], <i>p</i> = .002 | 1.35, 95% CI [1.14, 1.60], <i>p</i> = .001 | 1.31, 95% CI [1.09, 1.56], <i>p</i> = .003 |
| UACR              | women: | 1.62, 95% CI [0.77, 3.40], <i>p</i> = .200 | 1.40, 95% CI [1.20, 1.63], <i>p</i> < .001 | 1.45, 95% CI [1.20, 1.74], <i>p</i> < .001 |
| ≥ upper quartile  | men:   | 1.72, 95% CI [0.77, 3.87], <i>p</i> = .188 | 1.40, 95% CI [1.18, 1.67], <i>p</i> < .001 | 1.37, 95% CI [1.14, 1.65], <i>p</i> = .001 |
| <b>Model (B).</b> |        |  |  |  |
| UOCR              | women: | 1.68, 95% CI [0.76, 3.73], <i>p</i> = .200 | 1.28, 95% CI [1.07, 1.51], <i>p</i> = .005 | 1.43, 95% CI [1.18, 1.74], <i>p</i> < .001 |
| ≥ upper quartile  | men:   | 3.73, 95% CI [1.59, 8.78], <i>p</i> = .003 | 1.29, 95% CI [1.09, 1.54], <i>p</i> = .005 | 1.33, 95% CI [1.11, 1.60], <i>p</i> = .002 |
| UACR              | women: | 1.65, 95% CI [0.76, 3.60], <i>p</i> = .205 | 1.30, 95% CI [1.10, 1.07], <i>p</i> = .002 | 1.38, 95% CI [1.14, 1.67], <i>p</i> = .001 |
| ≥ upper quartile  | men:   | 1.46, 95% CI [0.62, 3.45], <i>p</i> = .384 | 1.37, 95% CI [1.14, 1.65], <i>p</i> = .001 | 1.35, 95% CI [1.11, 1.64], <i>p</i> = .003 |
| <b>Model (C).</b> |        |  |  |  |
| UOCR              | women: | 1.37, 95% CI [0.59, 3.18], <i>p</i> = .466 | 1.23, 95% CI [1.03, 1.47], <i>p</i> = .020 | 1.36, 95% CI [1.11, 1.67], <i>p</i> = .003 |
| ≥ upper quartile  | men:   | 3.75, 95% CI [1.55, 9.07], <i>p</i> = .003 | 1.20, 95% CI [1.00, 1.44], <i>p</i> = .045 | 1.20, 95% CI [0.99, 1.45], <i>p</i> = .061 |
| UACR              | women: | 1.73, 95% CI [0.77, 3.88], <i>p</i> = .182 | 1.27, 95% CI [1.07, 1.49], <i>p</i> = .005 | 1.30, 95% CI [1.06, 1.59], <i>p</i> = .010 |
| ≥ upper quartile  | men:   | 1.31, 95% CI [0.53, 3.20], <i>p</i> = .559 | 1.26, 95% CI [1.04, 1.53], <i>p</i> = .019 | 1.18, 95% CI [0.96, 1.45], <i>p</i> = .113 |
| <b>Model (D).</b> |        |  |  |  |
| UOCR              | women: | 1.39, 95% CI [0.59, 3.28], <i>p</i> = .453 | 1.20, 95% CI [1.01, 1.44], <i>p</i> = .038 | 1.34, 95% CI [1.09, 1.65], <i>p</i> = .005 |
| ≥ upper quartile  | men:   | 3.18, 95% CI [1.27, 7.95], <i>p</i> = .013 | 1.19, 95% CI [0.99, 1.42], <i>p</i> = .067 | 1.19, 95% CI [0.98, 1.45], <i>p</i> = .077 |
| UACR              | women: | 1.74, 95% CI [0.78, 3.91], <i>p</i> = .178 | 1.24, 95% CI [1.05, 1.46], <i>p</i> = .010 | 1.31, 95% CI [1.07, 1.60], <i>p</i> = .008 |
| ≥ upper quartile  | men:   | 1.21, 95% CI [0.48, 3.06], <i>p</i> = .693 | 1.28, 95% CI [1.05, 1.56], <i>p</i> = .013 | 1.18, 95% CI [0.96, 1.45], <i>p</i> = .116 |


Model (A) Adjusted for age. Model (B) Adjusted for (A) plus hypertension and UACR as a continuous variable in the analysis for UOCR ≥ upper quartile, and for UOCR as a continuous variable in the analysis of UACR ≥ upper quartile. Model (C) Adjusted for (B) plus diabetes, body mass index, smoking and, cholesterol. Model (D) Adjusted for (C) plus eGFR. UOCR: urinary orosomucoid to creatinine ratio, UACR: urinary albumin to creatinine ratio. IMT: Intima media thickness. UOCR/UACR quartiles: we used sex specific values. eGFR: estimated glomerular filtration rate.

The cross-sectional design limits conclusions about the temporal relationship between the biomarkers and the endpoints. Causal inferences can never be made from observational studies.

Because cross-sectional studies are shorter and therefore cheaper to carry out, they can be used to discover correlations that can then be investigated in a longitudinal study.


### Cross-sectional study

Data collected at one point in time



### Longitudinal study

Data collected repeatedly over time





# Jobber med andre artikkel:

## Er det sammenheng mellom orosomuroid i urin og reduksjon av nyrefunksjon?

- Longitudinal study
- Følger de samme personene over år for å undersøke sammenhenger over tid


# Måle nyrefunksjonen

- Gullstandard for å måle nyrenes filtrasjon (GFR) gjøres ved å injisere ett stoff som
  - kun elimineres via nyrene,
  - filtreres fritt i glomeruli,
  - og hverken blir reabsorbert eller skilt ut i nyretubuli.
- I Norge, Iohexol, DTPA og EDTA



## RENIS:

- Renal
- Iohexol Clearance
- Survey
  
- Måler nyrefunksjonen (GFR) i stedet for som vi snakket om tidligere der nyrefunksjonen ble estimert med bakgrunn måling av kreatinin i blod
- Renis-kohort: følges over mange år





# Statistiske analyser

- Study characteristics
  - mean (standard deviation, SD) if normally distributed
  - medians (interquartile range, IQR) in case of a skewed distribution
  - independent sample t-tests, Mann-Whitney U tests, one-way ANOVA and chi-squared test
  - linear trend across quartiles of UOCR linear-by-linear and Cochran-Armitage test were used for continuous and categorical data respectively
- GFR slope: linear mixed model, using all available GFR measurements
- Linear mixed model regression
- Multiple logistic regression models



UiT The Arctic University of Norway



HELGELANDSSYKEHUSET  
HELGELAND HOSPITAL TRUST



# ASSOCIATION OF URINARY BIOMARKERS AND ACCELERATED, AGE-RELATED DECLINE IN MEASURED GFR.

Runa M. Andreassen

*Department of Internal Medicine, Helgeland Hospital Trust, Sandnessjøen, Norway*

*Metabolic and Renal Research Group, UiT The Arctic University of Norway, Tromsø, Norway*



# Results

Adjusted for age and sex

- Lower GFR

UOCR:

A doubling ( $\log_2$ ) of baseline values was associated with lower GFR:

- 0.63ml/min/1,73m<sup>2</sup>,  $p=0.002$ , 95% CI -1.03, -0.23

UACR:

No association was found between UACR and lower GFR ( $p=0.670$ ).

- Accelerated annual GFR decline

UOCR:

Each  $\log_2$  UOCR was associated with accelerated annual GFR decline of:

- 0.06 ml ( $p=0.011$ , 95%CI -0.10,-0.01)

UACR:

No association was found between  $\log_2$ UACR and accelerated annual GFR decline ( $p=0.107$ )



# Planlegger 3.artikkel

- Longitudinal
- Multivariable Cox regression analyses
- Undersøke om orosomucoid er en prediktor for
  - first-ever myocardial infarction,
  - first-ever ischaemic stroke and
  - or all-cause mortality
- Sendt inn abstract til

60<sup>TH</sup> ERA  
CONGRESS  
MILAN & VIRTUAL  
JUNE 15-18, 2023